Brentuximab Vedotin Plus AVD in Non-bulky Limited Stage Hodgkin Lymphoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2017
At a glance
- Drugs Brentuximab vedotin (Primary) ; Dacarbazine; Doxorubicin; Vinblastine
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 08 May 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 17 Dec 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jan 2017.